ANI Pharmaceuticals, Inc.

ANIP

$74.43

Updated: 24/09/2026, 08:14:20

Market Cap

$1.69B

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

Stock valuation chart

One-year closing share-price history for ANIP

Company Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

USD

NASDAQ

CEO: Nikhil Lalwani

Employees: 970

https://www.anipharmaceuticals.com

Asset Summaries

Latest generated summaries for ANIP

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for ANIP.

Share price: $74.43
Market cap: $1.69B
Exchange: NASDAQ
Currency: USD
CEO: Nikhil Lalwani
Employees: 970
IPO date: 05/05/2000
Beta: 0.45
Last dividend: $0.00
Day range: $74.21 – $78.86
52-week range: $69.58 – $97.00
1-day performance: -4.47%
1-year performance: 6.97%
Current drawdown (1Y): -23.27%
CIK: 0001023024
CUSIP: 00182C103
ISIN: US00182C1036
Created: 07/12/2025, 02:05:24
Last update: 24/09/2026, 08:14:20

Track ANI Pharmaceuticals, Inc. with an AI analyst

See which prediction-market events move ANIP, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to ANIP from your Railway `news_articles` table.

Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?

Zacks Investment Research • STOCK • 10/06/2026, 16:30:30

ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push

Zacks Investment Research • STOCK • 10/06/2026, 16:26:04

ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth

Zacks Investment Research • STOCK • 10/06/2026, 16:21:17

Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term

Zacks Investment Research • STOCK • 29/05/2026, 12:46:14

ANIP Valuation: Does 9.8x Forward P/E Offer Upside?

Zacks Investment Research • STOCK • 15/05/2026, 14:47:07

ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge

Zacks Investment Research • STOCK • 15/05/2026, 14:40:57

ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Shows Strong Financial Health Amidst Insider and Institutional Sales

Market Data • Market Data • 13/05/2026, 23:13:22

ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research • STOCK • 13/05/2026, 12:51:12

ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised

Zacks Investment Research • STOCK • 11/05/2026, 14:31:30

ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 08/05/2026, 14:51:21

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

Zacks Investment Research • STOCK • 08/05/2026, 11:05:48

ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance

GlobeNewsWire • STOCK • 08/05/2026, 08:50:00